30 July 2026
30 July 2026
The Axogen investment will be used to progress the technology into Phase II and III clinical studies.
The trial is already active at UC Davis Comprehensive Cancer Center.
The financing supports Phase II clinical development of CLD-423 in ulcerative colitis and Crohn’s disease.
The study will enrol around 1,000 participants at up to 100 sites across Canada, Europe, and the US.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
